2023-06-012024-05-312024-05-31false06189780LR CLINICAL SOLUTIONS LIMITED2025-02-1382990falseiso4217:GBPxbrli:pure061897802023-06-01061897802024-05-31061897802023-06-012024-05-31061897802022-06-01061897802023-05-31061897802022-06-012023-05-3106189780bus:SmallEntities2023-06-012024-05-3106189780bus:AuditExempt-NoAccountantsReport2023-06-012024-05-3106189780bus:FullAccounts2023-06-012024-05-3106189780bus:PrivateLimitedCompanyLtd2023-06-012024-05-3106189780core:WithinOneYear2024-05-3106189780core:AfterOneYear2024-05-3106189780core:WithinOneYear2023-05-3106189780core:AfterOneYear2023-05-3106189780core:ShareCapital2024-05-3106189780core:SharePremium2024-05-3106189780core:RevaluationReserve2024-05-3106189780core:OtherReservesSubtotal2024-05-3106189780core:RetainedEarningsAccumulatedLosses2024-05-3106189780core:ShareCapital2023-05-3106189780core:SharePremium2023-05-3106189780core:RevaluationReserve2023-05-3106189780core:OtherReservesSubtotal2023-05-3106189780core:RetainedEarningsAccumulatedLosses2023-05-3106189780core:LandBuildings2024-05-3106189780core:PlantMachinery2024-05-3106189780core:Vehicles2024-05-3106189780core:FurnitureFittings2024-05-3106189780core:OfficeEquipment2024-05-3106189780core:NetGoodwill2024-05-3106189780core:IntangibleAssetsOtherThanGoodwill2024-05-3106189780core:ListedExchangeTraded2024-05-3106189780core:UnlistedNon-exchangeTraded2024-05-3106189780core:LandBuildings2023-05-3106189780core:PlantMachinery2023-05-3106189780core:Vehicles2023-05-3106189780core:FurnitureFittings2023-05-3106189780core:OfficeEquipment2023-05-3106189780core:NetGoodwill2023-05-3106189780core:IntangibleAssetsOtherThanGoodwill2023-05-3106189780core:ListedExchangeTraded2023-05-3106189780core:UnlistedNon-exchangeTraded2023-05-3106189780core:LandBuildings2023-06-012024-05-3106189780core:PlantMachinery2023-06-012024-05-3106189780core:Vehicles2023-06-012024-05-3106189780core:FurnitureFittings2023-06-012024-05-3106189780core:OfficeEquipment2023-06-012024-05-3106189780core:NetGoodwill2023-06-012024-05-3106189780core:IntangibleAssetsOtherThanGoodwill2023-06-012024-05-3106189780core:ListedExchangeTraded2023-06-012024-05-3106189780core:UnlistedNon-exchangeTraded2023-06-012024-05-3106189780core:MoreThanFiveYears2023-06-012024-05-3106189780core:Non-currentFinancialInstruments2024-05-3106189780core:Non-currentFinancialInstruments2023-05-3106189780dpl:CostSales2023-06-012024-05-3106189780dpl:DistributionCosts2023-06-012024-05-3106189780core:LandBuildings2023-06-012024-05-3106189780core:PlantMachinery2023-06-012024-05-3106189780core:Vehicles2023-06-012024-05-3106189780core:FurnitureFittings2023-06-012024-05-3106189780core:OfficeEquipment2023-06-012024-05-3106189780dpl:AdministrativeExpenses2023-06-012024-05-3106189780core:NetGoodwill2023-06-012024-05-3106189780core:IntangibleAssetsOtherThanGoodwill2023-06-012024-05-3106189780dpl:GroupUndertakings2023-06-012024-05-3106189780dpl:ParticipatingInterests2023-06-012024-05-3106189780dpl:GroupUndertakingscore:ListedExchangeTraded2023-06-012024-05-3106189780core:ListedExchangeTraded2023-06-012024-05-3106189780dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-06-012024-05-3106189780core:UnlistedNon-exchangeTraded2023-06-012024-05-3106189780dpl:CostSales2022-06-012023-05-3106189780dpl:DistributionCosts2022-06-012023-05-3106189780core:LandBuildings2022-06-012023-05-3106189780core:PlantMachinery2022-06-012023-05-3106189780core:Vehicles2022-06-012023-05-3106189780core:FurnitureFittings2022-06-012023-05-3106189780core:OfficeEquipment2022-06-012023-05-3106189780dpl:AdministrativeExpenses2022-06-012023-05-3106189780core:NetGoodwill2022-06-012023-05-3106189780core:IntangibleAssetsOtherThanGoodwill2022-06-012023-05-3106189780dpl:GroupUndertakings2022-06-012023-05-3106189780dpl:ParticipatingInterests2022-06-012023-05-3106189780dpl:GroupUndertakingscore:ListedExchangeTraded2022-06-012023-05-3106189780core:ListedExchangeTraded2022-06-012023-05-3106189780dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2022-06-012023-05-3106189780core:UnlistedNon-exchangeTraded2022-06-012023-05-3106189780core:NetGoodwill2024-05-3106189780core:IntangibleAssetsOtherThanGoodwill2024-05-3106189780core:LandBuildings2024-05-3106189780core:PlantMachinery2024-05-3106189780core:Vehicles2024-05-3106189780core:FurnitureFittings2024-05-3106189780core:OfficeEquipment2024-05-3106189780core:AfterOneYear2024-05-3106189780core:WithinOneYear2024-05-3106189780core:ListedExchangeTraded2024-05-3106189780core:UnlistedNon-exchangeTraded2024-05-3106189780core:ShareCapital2024-05-3106189780core:SharePremium2024-05-3106189780core:RevaluationReserve2024-05-3106189780core:OtherReservesSubtotal2024-05-3106189780core:RetainedEarningsAccumulatedLosses2024-05-3106189780core:NetGoodwill2023-05-3106189780core:IntangibleAssetsOtherThanGoodwill2023-05-3106189780core:LandBuildings2023-05-3106189780core:PlantMachinery2023-05-3106189780core:Vehicles2023-05-3106189780core:FurnitureFittings2023-05-3106189780core:OfficeEquipment2023-05-3106189780core:AfterOneYear2023-05-3106189780core:WithinOneYear2023-05-3106189780core:ListedExchangeTraded2023-05-3106189780core:UnlistedNon-exchangeTraded2023-05-3106189780core:ShareCapital2023-05-3106189780core:SharePremium2023-05-3106189780core:RevaluationReserve2023-05-3106189780core:OtherReservesSubtotal2023-05-3106189780core:RetainedEarningsAccumulatedLosses2023-05-3106189780core:NetGoodwill2022-06-0106189780core:IntangibleAssetsOtherThanGoodwill2022-06-0106189780core:LandBuildings2022-06-0106189780core:PlantMachinery2022-06-0106189780core:Vehicles2022-06-0106189780core:FurnitureFittings2022-06-0106189780core:OfficeEquipment2022-06-0106189780core:AfterOneYear2022-06-0106189780core:WithinOneYear2022-06-0106189780core:ListedExchangeTraded2022-06-0106189780core:UnlistedNon-exchangeTraded2022-06-0106189780core:ShareCapital2022-06-0106189780core:SharePremium2022-06-0106189780core:RevaluationReserve2022-06-0106189780core:OtherReservesSubtotal2022-06-0106189780core:RetainedEarningsAccumulatedLosses2022-06-0106189780core:AfterOneYear2023-06-012024-05-3106189780core:WithinOneYear2023-06-012024-05-3106189780core:Non-currentFinancialInstrumentscore:CostValuation2023-06-012024-05-3106189780core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-06-012024-05-3106189780core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-06-012024-05-3106189780core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-06-012024-05-3106189780core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-06-012024-05-3106189780core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-06-012024-05-3106189780core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-06-012024-05-3106189780core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-06-012024-05-3106189780core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-06-012024-05-3106189780core:Non-currentFinancialInstrumentscore:CostValuation2024-05-3106189780core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-05-3106189780core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-05-3106189780core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-05-3106189780core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-05-3106189780core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-05-3106189780core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-05-3106189780core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-05-3106189780core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-05-3106189780core:Non-currentFinancialInstrumentscore:CostValuation2023-05-3106189780core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-05-3106189780core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-05-3106189780core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-05-3106189780core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-05-3106189780core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-05-3106189780core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-05-3106189780core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-05-3106189780core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-05-3106189780bus:Director12023-06-012024-05-31

LR CLINICAL SOLUTIONS LIMITED

Registered Number
06189780
(England and Wales)

Unaudited Financial Statements for the Year ended
31 May 2024

LR CLINICAL SOLUTIONS LIMITED
Company Information
for the year from 1 June 2023 to 31 May 2024

Director

RAHAMAN, Lutfat

Registered Address

Whiteleaf Business Centre
11 Little Balmer
Buckingham
MK18 1TF

Registered Number

06189780 (England and Wales)
LR CLINICAL SOLUTIONS LIMITED
Balance Sheet as at
31 May 2024

Notes

2024

2023

£

£

£

£

Fixed assets
Tangible assets31,231933
1,231933
Current assets
Stocks4-3,875
Debtors28,14110,884
Cash at bank and on hand9242,120
28,23356,879
Creditors amounts falling due within one year5(24,736)(45,452)
Net current assets (liabilities)3,49711,427
Total assets less current liabilities4,72812,360
Net assets4,72812,360
Capital and reserves
Called up share capital11
Profit and loss account4,72712,359
Shareholders' funds4,72812,360
The financial statements were approved and authorised for issue by the Director on 13 February 2025, and are signed on its behalf by:
RAHAMAN, Lutfat
Director
Registered Company No. 06189780
LR CLINICAL SOLUTIONS LIMITED
Notes to the Financial Statements
for the year ended 31 May 2024

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in compliance with FRS 102 Section 1A as it applies to the financial statements for the period and there were no material departures from the reporting standard.
Revenue from rendering of services
Revenue from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs. Turnover is only recognised to the extent of recoverable expenses when the outcome of a contract cannot be estimated reliably.
Foreign currency translation
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
Tangible fixed assets and depreciation
Tangible fixed assets are stated at cost or valuation less depreciation. Depreciation is provided on all tangible fixed assets as follows:

Straight line (years)
Office Equipment3
Stocks and work in progress
Inventories are valued at the lower of cost and estimated selling price (less any associated costs to enable such sales to complete).
2.Average number of employees

20242023
Average number of employees during the year11
3.Tangible fixed assets

Office Equipment

Total

££
Cost or valuation
At 01 June 231,3991,399
Additions949949
At 31 May 242,3482,348
Depreciation and impairment
At 01 June 23466466
Charge for year651651
At 31 May 241,1171,117
Net book value
At 31 May 241,2311,231
At 31 May 23933933
4.Stocks

2024

2023

££
Work in progress-3,875
Total-3,875
5.Creditors: amounts due within one year

2024

2023

££
Trade creditors / trade payables1110
Taxation and social security23,32444,042
Accrued liabilities and deferred income1,4011,400
Total24,73645,452
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.